FDA Grants Fast Track Designation to Galinpepimut-S in Multiple Myeloma

July 30, 2018 – The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to galinpepimut-S for the treatment of multiple myeloma. Galinpepimut-S is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms tumor 1 (WT1) protein, which is present in an array of tumor types. Final clinical and immunologic data from a phase II clinical trial for galinpepimut-S in the treatment of high-risk multiple myeloma was presented at the 44th … (leggi tutto)